MARKET

PALI

PALI

Palisade Bio Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5051
+0.0132
+2.68%
After Hours: 0.5000 -0.0051 -1.01% 18:16 05/25 EDT
OPEN
0.4850
PREV CLOSE
0.4919
HIGH
0.5490
LOW
0.4850
VOLUME
87.88K
TURNOVER
0
52 WEEK HIGH
4.570
52 WEEK LOW
0.4000
MARKET CAP
11.05M
P/E (TTM)
-0.1659
1D
5D
1M
3M
1Y
5Y
BRIEF-Palisade Bio Reports Qtrly Loss Per Share $0.26
reuters.com · 05/13 13:08
Palisade Bio GAAP EPS of -$0.26 beats by $0.02
Palisade Bio press release (NASDAQ:PALI): Q1 GAAP EPS of -$0.26 beats by $0.02. As of March 31, 2022, the Company had cash and cash equivalents of $6.6 million Shares -3.29%
Seekingalpha · 05/13 13:04
-- Earnings Flash (PALI) PALISADEBIO Posts Q1 Loss $-0.26
MT Newswires · 05/13 09:11
Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires
CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it had made equity grants to four new ...
GlobeNewswire · 05/10 21:00
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 05/09 12:18
92 Biggest Movers From Friday
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the commercialization of space technologies and services.
Benzinga · 05/09 10:27
BRIEF-Palisade Bio Announces $2 Mln Registered Direct Offering
reuters.com · 05/06 13:46
Palisade Bio to raise $2M in stock offering
Palisade Bio (NASDAQ:PALI) trades 11.3% down premarket after it entered into definitive agreements with several institutional and accredited investors for the purchase and sale in a registered direct offering of 3.65M shares at
Seekingalpha · 05/06 12:47
More
No Data
Learn about the latest financial forecast of PALI. Analyze the recent business situations of Palisade Bio Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PALI stock price target is 4.000 with a high estimate of 5.00 and a low estimate of 3.000.
High5.00
Average4.000
Low3.000
Current 0.5051
EPS
Actual
Estimate
-2.72-1.91-1.10-0.29
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 47
Institutional Holdings: 954.77K
% Owned: 4.36%
Shares Outstanding: 21.88M
TypeInstitutionsShares
Increased
8
87.14K
New
2
70.83K
Decreased
4
146.00K
Sold Out
5
435.91K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.55%
Pharmaceuticals & Medical Research
+0.01%
Key Executives
Chairman/Director
James Neal
President/Chief Operating Officer
Matthew Kalnik
Chief Executive Officer/Chief Financial Officer/Chief Accounting Officer
Dane Saglio
Chief Executive Officer/Director
Thomas Hallam
Director
Stephanie Diaz
Director
Robert Trenschel
Director
Don Williams
Independent Director
Cristina Csimma
Independent Director
Mary Gray
Independent Director
Binxian Wei
No Data
No Data
About PALI
Palisade Bio, Inc, formerly Seneca Biopharma, Inc., is a biopharmaceutical company. The Company is focused on developing therapies that helps patients with acute and chronic gastrointestinal problems from post-operative digestive enzyme damage. Its product candidate, LB1148, is a Phase III-ready protease inhibitor which is developed to reduce abdominal adhesions and help restore bowel function following surgery. It is engaged in developing oral product candidates to treat conditions driven by protease (intestinal digestive enzymes) escaping the intestines, including surgical problems and inflammatory conditions. Its LB1148 is an oral formulation of a serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery.

Webull offers kinds of Palisade Bio Inc stock information, including NASDAQ:PALI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PALI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PALI stock methods without spending real money on the virtual paper trading platform.